Navigation Links
OnSiteRx® Launches First for Arizona: Automated Drug Dispensing in Nursing Home
Date:2/16/2012

DALLAS and FORT WORTH, Texas, Feb. 16, 2012 /PRNewswire/ -- OnSiteRx®, Inc. (http://www.onsiterx.com), parent organization for OnSiteRx® of Phoenix, LLC, in partnership with Covenant Health Network, announces today that they have successfully implemented the first automated drug dispensing system to operate in a long-term care facility in the state of Arizona.

"It is not often when healthcare can increase patient safety and lower medication cost," states Dr. Reef Gillum, Founder and CEO of OnSiteRx®. "This is a giant step for healthcare in Arizona. The system transforms a 30-year-old antiquated process by providing daily dispensed, individually packaged, pharmacist-reviewed medication within minutes, significantly increasing safety, decreasing drug waste and improving documentation."

OnSiteRx's ODS™ (OnSiteRx Dispensing System™) was fully operational at the Christian Care Nursing Center in Phoenix, Arizona on Wednesday, February 1, 2012. Through its own patent-pending web-based software application, the system remotely communicates to a dispensing packager positioned in a secured location at the facility. OnSiteRx's local pharmacy closely monitors and supplies the inventory within the packager, and handles all emergency deliveries for the facility as well.

Matt Luger, CEO of the Phoenix-based non-profit organization Covenant Health Network, states, "This new model of medication administration will revolutionize the way pharmacy services are provided in senior care settings. First dose orders can be processed and are available for the nursing staff to pass immediately, rather than having to wait hours for an off-site pharmacy courier to deliver. Medications are dispensed and the facility or resident is charged only as used, rather than a week or month in advance. Nursing staff time saved, due to the reduction in the length of each med pass, can be re-directed to more resid
'/>"/>

SOURCE OnSiteRx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
2. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
3. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
4. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
5. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
6. deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack
7. Premier Micronutrient Launches Supplement for Hearing Health
8. deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
9. PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs
10. Seal Shield Launches Worlds First Antibacterial, Dishwasher Safe Keyboard and Mouse for Infection Control
11. PositiveFriends.com Launches STD Social Networking Site Balancing Dating with Online Support Features
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014 Research and Markets has announced ... Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023" ... of this report, the human microbiome market is segmented by ... market is expected to be valued as $294 million in ... 22.3% within the forecast period of 2019-2023. The market is ...
(Date:9/19/2014)... Sept. 19, 2014 UBM Medica US announces ... online community to help oncologists and other clinicians gain ... the use of targeted therapies and immunotherapies, discusses some ... treatment.  Every September, Blood Cancer ... raise awareness about blood cancers—helping to increase survival rates ...
(Date:9/19/2014)... Sept. 19, 2014  Alere Inc. (NYSE: ... the following statement today in support of President ... "As the global leader in rapid diagnostics for ... national strategy to address the serious threat of antibiotic ... the Administration on initiatives to promote the development of ...
Breaking Medicine Technology:Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2
... LAIYANG, China , May 17 /PRNewswire-Asia-FirstCall/ -- ... pharmaceutical company with its principal operations in the People,s,Republic ... quarter,fiscal year 2010 ended March 31, 2010 . , ... -- Revenue was $25.6 million, a slight decrease of 0.6% ...
... Connecticut waterways may be safer from biomedical waste, thanks to ... CEDF, with loan-program partners, Connecticut ,s Department of Economic and Community and ... to a West Haven company that stems improper disposal of needles ... West Haven ...
Cached Medicine Technology:Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 2Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 3Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 4Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 5Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 6Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 7Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 8Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 9Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 10Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 11Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 12Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 13Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 14Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 15Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 16Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 17Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 18Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 19Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 20Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 21West Haven Firm Expands Biomedical Disposal Program with Community Economic Development Fund 2
(Date:9/19/2014)... Dartmouth researcher, working with The Melanoma Genetics Consortium, GenoMEL, ... in the Journal of the National Cancer Institute ... melanoma. , "For the first time, we have established ... play a part in the risk of developing melanoma," ... School of Medicine at the University of Leeds (UK). ...
(Date:9/19/2014)... 2014 According to a report from ... blood-thinner Xarelto, named as defendants in several lawsuits filed ... moved the court to dismiss those suits because the ... connection with Philadelphia.* The cases include, for instance, Fontan ... Pa. Comm. Pls., Philadelphia Cty.), which was brought by ...
(Date:9/19/2014)... FRIDAY, Sept. 19, 2014 (HealthDay News) -- U.S. military ... risk of skin cancer, according to a new study. ... serving abroad, researchers revealed. In some cases, military personnel ... in the color, shape or size of their moles ... can be risk factors for skin cancer, the study ...
(Date:9/19/2014)... 19, 2014 (HealthDay News) -- Pregnant women who live in ... low birth weight babies, a new study suggests. Researchers ... and found that expectant mothers who lived in a neighborhood ... 20 percent lower risk of very preterm birth (before 30 ... birth (30 to 36 weeks). Babies born to mothers ...
(Date:9/19/2014)... News) -- The U.S. Food and Drug Administration approved a ... part of a class of once-a-week injectable drugs that help ... "Trulicity is a new treatment option, which can ... control blood sugar levels in the overall management of type ... Office of Drug Evaluation II, said in an agency news ...
Breaking Medicine News(10 mins):Health News:Melanoma risk found to have genetic determinant 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 3Health News:Some U.S. Troops May Face Greater Skin Cancer Risk 2Health News:Do Greener Neighborhoods Produce Healthier Babies? 2Health News:FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes 2
... obesity, diabetes ... and heart disease, MINNEAPOLIS/ST. ... Minnesota,s Tucker Center for Research on Girls &,Women in Sport shows ... in physical activity outside of organized,sports is declining, especially as they ...
... Get ready to feel good. That,s the,mantra for ... feel good these days. The national March of Dimes ... a debut fundraiser called,"Stork Tunes." Just in time for ... will fund the nonprofit,s efforts to give every baby ...
... research,organization, announced that it has opened a new office ... Alexey V. Kornilov as,General Manager of its Russian operations., ... the leadership of Alexey,V. Kornilov, MD and will be ... Kornilov brings over 10 years of clinical,experience to Chiltern ...
... of SEIU Staff Bused in to Smash Into Meeting to ... Break ... The California Nurses,Association/National Nurses Organizing Committee tonight condemned a ... Employees,International Union who smashed into a conference of union members ...
... Cancer Institute researchers have found that a tumor protein ... related to a poor prognosis. , The presence ... referred to as GRB-7, in breast cancer tumors, is ... cancer, according to principal investigator Shiuh-Wen Luoh, M.D., Ph.D., ...
... among women with HER2 malignancies, study shows , , SUNDAY, ... significantly reduced the risk of recurrence for patients who ... , This type of breast cancer, representing about one-quarter ... forms of the disease. In this group, the vaccine ...
Cached Medicine News:Health News:Girls in Sports at Record High, Yet Many Girls Fail to Meet Minimal Standards of Physical Activity, University of Minnesota Report Says 2Health News:Girls in Sports at Record High, Yet Many Girls Fail to Meet Minimal Standards of Physical Activity, University of Minnesota Report Says 3Health News:Northwest Songwriter Dean Backholm Featured on National March of Dimes CD 2Health News:Chiltern Opens a New Office in Russia 2Health News:CNA/NNOC: RNs Condemn Violent Service Union Attack at Michigan Event 2Health News:CNA/NNOC: RNs Condemn Violent Service Union Attack at Michigan Event 3Health News:OHSU Cancer Institute researchers find connection between protein, prognosis in breast cancer 2Health News:Breast Cancer Vaccine Works Against Deadlier Form of Disease 2Health News:Breast Cancer Vaccine Works Against Deadlier Form of Disease 3
... The MICROM CTM 6 is a highly efficient ... and Cytology laboratories. The instrument is capable ... with continuous slide rack loading capabilities. The slide ... 30 slides each. User intuitive operation is made ...
... Miniaturized robotic system for spinal procedures. The ... a highly accurate, easy-to-use solution that enables ... and minimum intervention. SpineAssist currently answers a ... use guidance devices in pedicle screw insertion ...
... The SENSAR® Acrylic IOL with OptiEdge offers ... long-term refractive stability, and excellent handling. The ... had no reports of vacuoles; the patented ... reflections and provide 360 degrees of contact ...
ACRYSOF® Posterior Chamber Intraocular Lenses are indicated for the replacement of the human lens to achieve visual correction of aphakia in patients sixty years and older. These lenses are inten...
Medicine Products: